0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

As Data on Antiprogesterone Compounds Grow, Societal and Scientific Aspects Are Scrutinized

Marsha F. Goldsmith
JAMA. 1991;265(13):1628-1629. doi:10.1001/jama.1991.03460130018004.
Text Size: A A A
Published online

ABSTRACT

ALTHOUGH some people wish it would just go away, a symposium at the American Association for the Advancement of Science meeting in Washington, DC, has presented new evidence for the argument that RU-486 (mifepristone) is here to stay.

Ever since the first reports were published in the early 1980s of this drug's use in France as a safe and effective abortifacient, researchers have also emphasized the many other potential indications inherent in the entire class of antiprogestational compounds (JAMA. 1989;262:1808-1814 and 1990;264:1026-1027). Now, the results of clinical trials of RU-486 for at least two gynecologic uses—ripening of the cervix at term and expulsion of the fetus after spontaneous intrauterine death during the second or third trimester-are so encouraging that its approval for these purposes appears to be "imminent."

That is the opinion of the symposium chair, Sheldon J. Segal, PhD. He says the French researchers have enough data now to

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();